CD33-targeted CAR-T cells have also been explored and proven effective [26, 27]; CD33-CART cells are being explored in multiple clinical trials for children and adults with relapsed/refractory AML (NCT03971799, NCT03927261). This evidence concerns the gene CD33 and acute myeloid leukemia.